2019 Future of Coronary Artery Disease (CAD)/Ischemic Heart Disease R&D Pipeline Drugs and Companies

2019 Future of Coronary Artery Disease (CAD)/Ischemic Heart Disease R&D Pipeline Drugs and Companies

  • January 2019 •
  • 120 pages •
  • Report ID: 5723835 •
  • Format: PDF
The global demand for Coronary Artery Disease (CAD) (Ischemic Heart Disease) treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline companies from advancing their products into Phase 3 or Phase 4.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Report Description-
The H1- 2019 pipeline review report on Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline compounds.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline guide presents information on all active drugs currently being developed for Coronary Artery Disease (CAD) (Ischemic Heart Disease). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Coronary Artery Disease (CAD) (Ischemic Heart Disease) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Coronary Artery Disease (CAD) (Ischemic Heart Disease) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline report includes-
- An overview of Coronary Artery Disease (CAD) (Ischemic Heart Disease) disease including symptoms, causes, diagnosis and available treatment options is provided.

- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

- Phase wise count of pipeline compounds

- Company wise list of pipeline compounds

- Mechanism of Action wise pipeline compounds

- For each pipeline product, the following details are provided-
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials

Reasons to Buy-
- The report is designed to help industry executives promote the success and continued growth of their organizations

- Get clear understanding of the entire Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline, with details on active projects

- Stay ahead of the competition through comprehensive knowledge of Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline progress

- Get in detail information of each product with updated information on each project along with key milestones

- Gain clear insights into the market through in-depth strategic analysis review

- Know the list of companies participating in global Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data

- Get trial information for each pipeline product under development

- Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.